Acetylcholinesterase inhibitors (AChEIs), which have beneficial effects on cognition function10, are currently approved for the treatment of Alzheimer’s disease (AD) and licensed for the treatment of vascular dementia, with several clinical benefits11, 12. The gene discussed is ACHE; the disease is Alzheimer disease.